Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

For important updates on recent policy changes, please click here for more details.

Merck
CN
HomeWebinarsA New Screening Approach for Lead Discovery: DNA-Encoded Library Technology

A New Screening Approach for Lead Discovery: DNA-Encoded Library Technology



WEBINAR

This webinar is presented in partnership with Dynabind. Our speakers cover best practices and new innovations in screening during lead discovery,  an important step of drug discovery workflow. You will learn about a new screening approach to facilitate faster and cheaper lead discovery. This talk also covers sustainability in addition to efficiency.

Who should watch?

Chemists and biologists interested in new technologies and innovative approaches for the screening step of drug discovery workflow.

Speakers

Mike Thompson

Mike Thompson

Dynabind

CEO

Originally from the US, Michael is a trained chemist from a family of entrepreneurs. In 2014 he began to lead the team in developing the business concept and securing funding, and has served as CEO since the company’s foundation in 2017. In addition to his administrative responsibilities, Michael still leads the computational chemistry and library design teams at DyNAbind.

Francesco Reddavide

Francesco Reddavide

Dynabind

Director of R&D

A biotechnologist from Italy, Francesco is the principle creator of DyNAbind’s Dynamic Library and Binding Profiler technologies. He has been with the team since the very beginning, and has served as Director of Research and Development since company foundation in 2017, where he continues to innovate novel DEL technologies.

John Fetter Ph.D

John Fetter Ph.D

Merck

Product Manager, Emerging Chemical Synthesis

John received his Ph.D. in biochemistry from Michigan State University where he studied cytochrome c oxidase with Shelagh Ferguson-Miller. Then he worked in drug discovery research at North Carolina State, SmithKline Beecham, and Taxolog. After that, he moved to Sigma-Aldrich, now known as Merck, where he worked on developing assays for pharmaceutical screening. He is currently a product manager in the emerging chemical synthesis where he develops products that use chemical synthesis for life science applications. Much of his focus has been on developing a portfolio of bioconjugation products. He has recently been working on making DNA-encoded libraries more accessible through their availability as off-the-shelf kits.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?